ADULT STEM CELLS/PROGENITOR CELLS AND STEM CELL PROTEINS FOR TREATMENT OF EYE INJURIES AND DISEASES - The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.

2013-02-14

20130039925

ALTERNATIVE PATHWAY SPECIFIC ANTIBODIES FOR TREATING ARTHRITIS - A method of selecting a genus of therapeutic antibodies includes selecting antibodies with the following criteria; a) do inhibit cell lysis under conditions wherein the alternative pathway is isolated from the classical pathway; and b) do not inhibit cell lysis under conditions wherein the classical pathway is isolated from the alternative pathway; and c) do not inhibit cell lysis under conditions wherein the classical pathway and alternative pathway are active; and d) do inhibit C3b produced exclusively by the alternative pathway;

2013-02-14

20130039926

HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF - Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.

2013-02-14

20130039927

ANTIGENIC MIMICS OF DISCONTINUOUS EPITOPES OF PATHOGEN RECOGNIZED BY BROADLY NEUTRALIZING ANTIBODIES - The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.

METHOD TREATING BREAST CANCER - The present invention relates, in general, to breast cancer and, in particular, to methods of treating breast cancer comprising administering to a subject in need thereof an agent that modulates signal transduction regulated by β-arrestin (e.g., β-arrestin 1). The invention further relates to methods of identifying compounds suitable for use in such methods.

Antibodies Against A Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof - The present application provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens, and uses thereof.

2013-02-14

20130039932

QUICKLY SOLUBLE ORAL FILM DOSAGE CONTAINING STEVIOSIDES AS A UNPLEASANT TASTE MASKING AGENT - Disclosed is a quickly soluble oral film dosage for masking a nasty taste, in particular, a quickly soluble oral film dosage comprising a stevioside based sweetener and a high potency sweetener in a ratio by weight (w/w) of 1:3 to 3:1, which may efficiently mask a bitter or nasty taste of a medicine and may be quickly dissolved in a mouth without water, thereby improving an aftertaste thereof thus enhancing dosage acceptability of a patient.

2013-02-14

20130039933

STING (STIMULATOR OF INTERFERON GENES), A REGULATOR OF INNATE IMMUNE RESPONSES - Novel molecules termed STING which include nucleic acids, polynucleotides, oligonucleotides, peptides, mutants, variants and active fragments thereof, modulate innate and adaptive immunity in a subject. STING compositions are useful for the treatment of an immune-related disorder, including treating and preventing infection by modulating immunity.

2013-02-14

20130039934

TREATMENT OF IGE-MEDIATED DISEASE - The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased IgE levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers.

2013-02-14

20130039935

INDUCTION OF TUMOR IMMUNITY BY VARIANTS OF FOLATE BINDING PROTEIN - The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.

2013-02-14

20130039936

IMMUNOGENIC POTE PEPTIDES AND METHODS OF USE - POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.

2013-02-14

20130039937

Peptide Sequences and Compositions - Provided is a polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences having at least 60% homology with any of SEQ ID 1-4, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-4 that has the same length as the epitope:

2013-02-14

20130039938

HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS - This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

2013-02-14

20130039939

LIPOPEPTIDE- AND LIPOPROTEIN-CONJUGATES AND ITS USE - The present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates. In particular, the present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates comprising a lipid-containing moiety representing an adjuvant moiety, a peptide or protein moiety whereby said peptide or protein moiety represents at least one antigenic structure, the antigen-moiety, and, optionally, a conjugate moiety, preferably a monodisperse polyethyleneglycol unit.

2013-02-14

20130039940

Homogenous Vaccine Composition Comprising a Conjugate of EGF and P64K for the Treatment of Tumors - A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans, and provides a vaccine preparation with more than one type of effective dose presentation which enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites.

Compositions and Methods for Self-Adjuvanting Vaccines against Microbes and Tumors - The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immuno stimulator intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracelluar signaling peptide must be present in a complex of three or more units in order to stimulate an immune response. Inserting this fusion construct into viruses like HIV-1 or introducing it into dendritic cells or tumor cells is predicted to lead to a positive therapeutic effect in humans, non-human mammals, birds, and fish.

Anti-Viral Compounds - Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

2013-02-14

20130039945

Anti-Viral Compounds - Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

NOVEL IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF - The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection.

2013-02-14

20130039948

Inhibition of TCR Signaling with Peptide Variants - The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCRαβ-CD3δε-CD3γε-ζζ signaling complex. Yet more specifically, the peptides act on the TCRα/CD3δε/ζζ signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions. Specifically, the compositions are useful in the treatment and/or prevention of a disease or condition where T cells are involved or recruited. The compositions of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).

2013-02-14

20130039949

IMMUNOMODULATING COMPOUNDS AND RELATED COMPOSITIONS AND METHODS - Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.

2013-02-14

20130039950

NETI-POT PACKET MIXTURE - A nasal rinse composition comprising about 54 to 90 wt. % of sodium chloride and about 10 to 46 wt. % of sodium bicarbonate, and a kit comprising a packet that contains the rinse composition and a nasal rinse dispenser.

2013-02-14

20130039951

Process Of Preparing A Stabilized And Solubilized Formulation Of Sirolimus Derivatives - Provided is a process for preparing a solubilized and stabilized formulation of a sirolimus derivative, which comprises the steps of a dissolving a sirolimus derivative in a solvent, and bring a solution of the sirolimus derivative into contact with a water-soluble carrier to disperse the sirolimus derivative in the water-soluble carrier, and a formulation of a sirolimus derivative with improved solubility and stability as prepared by the preparation process as above.

2013-02-14

20130039952

CALCIPOTRIOL MONOHYDRATE NANOCRYSTALS - Calcipotriol monohydrate nanocrystals prepared by the process disclosed herein may be incorporated in a pharmaceutical composition for use in the prevention or treatment of dermal diseases and conditions.

2013-02-14

20130039953

METHOD FOR TREATING A SURFACE WITH A COATING COMPRISING A THERAPEUTIC AGENT AND DEVICE WITH TREATED SURFACE - A method for treating a surface with a therapeutic agent is disclosed. The method comprises precipitating a therapeutic agent from a hydrophilic polymeric base layer with which the therapeutic agent has been complexed, to form a layer comprising microparticles of the therapeutic agent on the hydrophilic polymeric base layer, the hydrophilic polymeric base layer being grafted to the surface. Devices comprising a surface having a hydrophilic polymeric base layer comprising a hydrophilic polymer grafted to the surface and a layer comprising microparticles of a therapeutic agent disposed on and complexed with the hydrophilic polymeric base layer are also disclosed.

Orally Ingested Metabolic Enhancer in Oral Thin Film Container - An orally ingestible energy-boosting device is provided for facilitating a temporary metabolic increase in a user. The device comprises a small container filled with an energy-enhancing substance. All or a portion of the small container is constructed of a water or saliva-soluble film that dissolves when placed in the mouth of a user. When the film dissolves, energy-enhancing substance is released into the mouth where it is absorbed. The small container may come in a variety of shapes and configurations to meet the varied energy boost needs of users.

2013-02-14

20130039956

USE OF NITROCARBOXYLIC ACIDS FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF AGGRESSIVE HEALING PATTERNS - The invention is directed to implants and medical devices having at least one layer which contains at least one nitrocarboxylic acid. These implants and medical devices shall be used for the prophylaxis and treatment of aggressive healing patterns. Furthermore, this invention relates to the use of nitrocarboxylic acids and their pharmaceutically acceptable salts as a therapeutic agent for the prophylaxis and treatment of a pathophysiological or non-physiological healing pattern due to exposure to a physical, chemical or thermal irritant of tissues, cells or organelles.

METHOD OF VACCINATION - The present invention relates to improved methods for vaccination of a subject. Particularly, the present invention discloses the use of skin antigen application to amplify and improve a pre-existing immunity against a selected pathogen in a subject. The present invention discloses the use of skin application in combination with conventional vaccination or priming for improved immunization or vaccination of a subject against a selected pathogen.

2013-02-14

20130039959

METHOD OF INHIBITING HIV AND BARRIER-FORMING COMPOSITION THEREFOR - A method for blocking, neutralizing, or killing human immunodeficiency virus (HIV) beginning prior to or during a human encountering an HIV contaminated environment or item includes: identifying a contaminated environment or item that is known or expected to be contaminated with HIV; and administering an effective amount of a barrier-forming composition to an oral or pharyngeal mucosa of the human prior to or during the human encountering the contaminated environment or item. The barrier-forming composition provides a barrier on the mucosa that inhibits the HIV from contacting the mucosa, and provides cidal or static activity against HIV. A method for preventing the transmission of HIV through oral sexual relations, and a sexually transmitted disease prophylactic device are also provided.

ENCAPSULATES - The present application relates to encapsulates, compositions, products comprising such encapsulates, and processes for making and using such encapsulates. Such encapsulates comprise a core comprising a perfume and a shell that encapsulates said core, such encapsulates may optionally comprise a parametric balancing agent, such shell comprising one or more azobenzene moieties.

METAL ENTRAPPED BIOACTIVE COMPOSITES - The present invention provides composites comprising at least one bioactive agent entrapped within a matrix of at least one metal; wherein said composite controllably releases at least one of said bioactive agent and metal or ion thereof, processes for the preparation of composites of the invention, compositions and products comprising composites of the invention and various uses thereof.

2013-02-14

20130039965

Coated Granular Material and Method for Producing Coated Granular Material - A coated granular material of the present invention includes: a water-soluble granular substance; a coating layer applied to at least a surface of the water-soluble granular substance and containing a thermosetting resin A formed from a resin liquid having a molar ratio A of isocyanate groups to hydroxyl groups of 0.5 to 0.99; and a protection layer applied to the coating layer and containing a thermosetting resin B formed from a resin liquid having a molar ratio B of isocyanate groups to hydroxyl groups of 0.75 to 2.0, wherein the molar ratio B of the protection layer is greater than the molar ratio A of the coating layer. The present coated granular material is capable of achieving both of a short-term release pattern and an initial release limiting function and maintaining good quality.

2013-02-14

20130039966

Bone Semi-Permeable Device - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.

MATERIALS AND PROCESSES FOR PRODUCING ANTITOXIC FABRICS - The invention provides a novel method of generating fabrics with outstanding antitoxic properties. The antitoxic properties are imparted to the fabric by introducing an active agent such as an antimicrobial or antiviral agent to the fabric. The active agent may be introduced into the fabric at multiple stages of the manufacturing process. For nonwoven fabrics, the active agent can be introduced during web formation and/or during post-processing steps. The fabrics produced in accordance with the present invention have widespread utility. For instance, they can be used as wound dressings, gowns, drapes, air filters, protective clothing and wipes.

2013-02-14

20130039969

Method And Composition For Treating Rhinitis - There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical acceptable aqueous carrier. The compositions are preferably homogeneous in their nature.

2013-02-14

20130039970

Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics - Processes and compositions for liposomal delivery of therapeuticals prepared by contacting an aqueous solution of an active agent with a solution of liposome-forming components containing one or more DILA2 amino acid compounds or lipids in organic solvent to form an impinging stream. A protocol including flow rates, pH, and an incubation period are used to control formation of liposomal components for therapeutic applications. The impinging stream may be collected and incubated to prepare a liposomal formulation which encapsulates the active agent. The composition can be quenched with buffer and filtered by tangential flow and diafiltration and other means for finishing as a pharmaceutical composition.

2013-02-14

20130039971

COMPOSITIONS AND METHODS FOR INHIBITION OF VEGF - Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.

2013-02-14

20130039972

COMPOSITIONS AND METHODS OF USE OF TARGETING PEPTIDES AGAINST PLACENTA AND ADIPOSE TISSUES - The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity. An exemplary placental receptor is FcRn/β

2013-02-14

20130039973

Viral Immunogenic Compositions - Disclosed herein are immunogenic compositions for producing immediate and sustained immunity to infectious viral and bacteriological pathogens. A univalent immunogenic composition is disclosed comprising an isolated antigen and a polynucleotide formulated into a nanoparticle or liposome. Furthermore, multivalent immunogenic compositions are disclosed comprising multiple univalent immunogenic compositions. Also disclosed, are methods of inducing protective or therapeutic immune responses in individuals comprising administering one or more univalent immunogenic compositions.

2013-02-14

20130039974

ANTI-MUC1 ANTIBODIES FOR CANCER DIAGNOSTICS - The present invention is directed to antibodies binding to the MUC1 cytoplasmic domain and methods of using such antibodies to treat, diagnose, detect and monitor cancers that express the MUC1 antigen.

PHARMACEUTICAL COMPOSITION, A METHOD OF PREPARING IT AND A METHOD OF TREATMENT BY USE THEREOF - Pharmaceutically acceptable liposome-encapsulated busulphan formulations for parenteral administration are provided, as well as such formulations furthermore comprising glutathione and/or at least one glutathione precursor and a process for manufacture of the preparations. The formulations are stable, have improved biodistribution and significantly reduced side effects over those produced by oral administration or parenteral administration of free drug. The formulations are useful as part of stem cell and/or bone marrow transplant conditioning regimens. A method of treatment of a mammal by use of such formulations.

Time Release Capsule for Beverage - This invention relates to time-release capsules administered in beverage preparations. The present invention may be used for administration of delayed-release flavor or color enhancement of the beverage preparation. It may also be used for the oral administration of pharmaceutical compounds, vitamins, or other active compounds, including herbal ingredients, to a person or animal in a liquid beverage. This invention solves several problems associated with the blending of complex drinks and taste habituation wherein the taste intensity of a drink decreases with time. It also solves several practical problems associated with administration of compounds to a person or veterinary patient, including reduction of efficacy due to manufacturing issues, suboptimal dissolution in the digestive system, and administration of an unpleasant oral compound in a form that is displeasing to taste.

2013-02-14

20130039981

Quick Dissolving, Long Acting Zinc Therapeutic Formulations - The present invention comprises a quick dissolving, long acting zinc therapeutic cold formulation containing high levels of an active compound encapsulated within bioadhesive/muco-adhesive polymers as a controlled release oral drug delivery system. The composition allows for increased residence time for enhanced prophylactic and therapeutic efficacy within the mouth and oral cavity. This allows for a reduction in the number of doses necessary to achieve therapeutic relief which will result in increased patience compliance.

2013-02-14

20130039982

LOW-DOSE TABLETS AND PREPARATION PROCESS - The invention concerns a microgranule tablet comprising a low dose of active principle containing a directly compressible diluent. The invention is characterised in that the directly compressible diluent consists exclusively of neutral microgranules, and the active principle is set on the neutral microgranules and is not coated with an agent designed to modify its release or mask its taste.

2013-02-14

20130039983

PROCESS FOR THE PRODUCTION OF RALFINAMIDE SALTS SUBSTANTIALLY FREE FROM IMPURITIES HAVING GENOTOXIC EFFECTS - The invention relates to a new process for the production and/or purification of the salt of the compound (S)-2-[4-(2-fluorobenzyloxy)benzylamino]propanamide, i.e. ralfinamide, or the respective R-enantiomer, with methanesulfonic acid in high yields and very high enantiomeric and chemical purity in the form of the crystalline anhydrous polymorph identified as form A, wherein said salt is substantially free from impurities having genotoxic effect, such as (C

Method for aligning cells and applying homogenous strain throughout deformable engineered tissue constructs - A process creates a homogenous sheet of engineered tissue comprised of encapsulated cells and a deformable engineered tissue construct. In the embodiment consisting of a collagen construct with encapsulated cells capable of contracting the matrix, the collagen fibers and encapsulated cells are aligned during the process. An apparatus can deliver controlled homogenous strain and stress to a thin sheet of engineered tissue. This process allows application of dynamic, uniform tensile loading to deformable engineered tissue constructs and creation of an engineered cell-delivery construct with alignment of both fibers and encapsulated cells.

2013-02-14

20130039986

Silk-Based Ionomeric Compositions - Disclosed herein are pH-dependent silk fibroin-based ionomeric compositions and colloids, and methods of making the same. The state of the silk fibroin ionomeric compositions is reversible and can transform from a gel-like colloid to a more fluid-like solution, or vice versa, upon an environmental stimulus, e.g., pH. Thus, the silk-based ionomeric compositions and colloids can be applied in various industries, ranging from electronic applications to biomedical applications, such as sensors, gel diodes, absorbent materials, drug delivery systems, tissue implants and contrast agents.

ACTIVE PELLET EXCLUDING CHEMICAL ADDITIVES - Disclosed herein is an active pellet. The active pellet includes a body and interspaces. The body includes an active ingredient ranging from 50 to 100 wt %, free of chemical additives.

2013-02-14

20130039989

PHARMACEUTICAL COMPOSITIONS COMPRISING N-(4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4-ETHOXY-1-(4-FLUO- ROPHENYL)-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE - Disclosed are salts and crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof. Also disclosed are at least one pharmaceutical composition comprising at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, at least one method of using at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide to treat cancer and/or other proliferative diseases, and processes to prepare crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof.

Elimination of N-Glycolylneuraminic Acid From Animal Products For Human Use - The application is in the field of transgenic (non-human) organisms, sialic acid chemistry, metabolism and antigenicity. More particularly, the invention is related to a method to produce Neu5Gc-free animals and products therefrom comprising disrupting the CMAH gene and thereby reducing or eliminating Neu5Gc from biological material of non-humans.

2013-02-14

20130039992

Honey-Based Gel Composition - A honey based composition is described. The composition includes a mixture of honey, a short chain fatty alcohol and a fatty ester or wax. The composition has applications for use in wound dressings and in one embodiment may be a gel. The composition has a higher than expected storage stability, remaining stable for many weeks when held at elevated temperatures and retains all of the other desirable characteristics including anti-microbial activity.

2013-02-14

20130039993

ARGON-BASED INHALABLE GASEOUS MEDICAMENT AGAINST PERIPHERAL ORGAN DEFICIENCIES OR FAILURES - The invention relates to a gaseous composition containing an effective amount of argon gas for use, by inhalation, in preventing or treating a deficiency or failure of at least one peripheral organ in a patient. Preferably, it contains between 15 and 80% by volume of argon, and oxygen, preferably at least 21% by volume of oxygen. The organ deficiency or failure thus treated is transient, preferably from less than one hour to a plurality of days or weeks, or definitive. The organ concerned may be the liver, the kidneys or the lungs.

2013-02-14

20130039994

LOW DOSE COLONIC CLEANSING SYSTEM - A method of colonic cleansing that includes administering orally a first dose and a second dose of a liquid osmotic colonic evacuant composition. The second dose includes an amount of the liquid osmotic colonic evacuant composition that is 55% to 95% of the amount of the first dose.

COMPOSITIONS OF MODULATORS OF THE WNT/BETA-CATENIN PATHWAY AND BENZAMIDE AND/OR HYDROXAMIC ACID DERIVATIVES TO TREAT BIPOLAR DISORDER - The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.

ANTIHYPERTENSIVE AGENTS - The present invention relates to an antihypertensive agent including a boysenberry seed extract as an active ingredient. According to the invention, there can be provided an effective and highly safe antihypertensive agent having antihypertensive effect so that the agent can contribute to the prevention and amelioration of hypertension and having very little risk of side effects even in continuous intake, and a method for producing the antihypertensive agent at low cost and efficiently.

Composite Sections for Aircraft Fuselages and Other Structures, and Methods and Systems for Manufacturing Such Sections - Composite sections for aircraft fuselages and other structures, and methods and systems for manufacturing such sections, are disclosed herein. A method for manufacturing a shell structure in accordance with one embodiment of the invention includes applying composite material to an interior mold surface of a tool to form a skin extending 360 degrees around an axis. The method can further include positioning a plurality of stiffeners on an inner surface of the skin. After the stiffeners have been positioned, a vacuum bag can be installed over the stiffeners and evacuated to press the stiffeners and the skin outwardly against the interior mold surface of the tool. Next, the skin/stiffener combination can be cocured to bond the stiffeners to the skin and harden the shell structure.

METHOD AND APPARATUS FOR FORMING SLATS FOR FABRIC IN COVERINGS FOR ARCHITECTURAL OPENINGS - A method and apparatus for forming a transversely curved or formed strip of material which can be cut to length for use in a fabric for coverings for architectural opening includes a supply role of a flexible fabric strip material that is sequentially passed through a heating chamber with an elongated upwardly convex extrusion across which the strip material is drawn and a cooling station before being wrapped on a take-up drum. The apparatus includes driven rollers about which the strip material passes and the strip material is exposed to tension detectors and controlled temperatures such that the strip material formed in the apparatus is uniform along its length.

2013-02-14

20130040011

APPARATUS FOR MANUFACTURING LIGHT GUIDE FILM - An apparatus for manufacturing a light guide film may comprise a feed roller, a receiving roller, a separating device, a hot press printing device and a recombining device. Firstly, the separating device may separate a protective layer from a substrate layer of the light guide film. Secondly, a surface of the substrate layer to be manufactured may be impressed with light guide dots by the hot press printing device, and the recombining device recombine the peeled protective layer to the substrate layer. And lastly, the finished light guide film is recycled by the receiving roller. The apparatus may have advantages such as high output and low cost, and it may manufacture a large dimensioned product.

2013-02-14

20130040012

COMPRESSION MOLDING APPARATUS AND MOLDING DIE - Disclosed are a compression molding apparatus and a molding die, whereby efficient hot-molding is performed. The compression molding apparatus performs a molding by providing a raw material into the molding die, and applying heat and pressure to the material. The apparatus is provided with: a first molding die, which forms a molding frame that surrounds a region where the raw material is compression-molded; a second molding die, which compresses the raw material provided into the molding frame; and a heat source section, which supports and heats the second molding die. The second molding die has: a first heat pipe, which has one end positioned on the heat source section side, and the other end positioned on the side of a pressing surface that presses the raw material; and a heat insulating layer, which wraps the first heat pipe along the longitudinal direction of the first heat pipe.

2013-02-14

20130040013

MOLD FOR PRODUCING MOLDED BLOCKS AND DEVICE FOR PRODUCING MOLDED BLOCKS - A mold (for producing molded blocks with at least one lateral face which has a texture, wherein the mold comprises at least one flexible belt, wherein the flexible belt surrounds at least one mold wall of the mold lower part that delimits the mold cavity in order to act on the material for producing the molded block that is received in the mold cavity, and in order in so doing to impress a texture on at least one of the lateral faces of the molded block, wherein the flexible belt can be moved relative to the mold lower part and wherein the flexible belt is mounted in such a way that it moves around the mold wall when the molded block is ejected from the mold cavity. Here, the mold comprises an active auxiliary device by means of which a rolling resistance of the flexible belt can be varied.

2013-02-14

20130040014

3-PLATE MOLD ASSEMBLY WITH A COMMON MOLD BASE - A 3-plate mold assembly with a common mold base comprises: a stationary mold mounted on a fixed side of an injection molding machine and a movable mold mounted on a movable side of the injection molding machine. The stationary mold comprises a stationary-side fixed plate on which are disposed four pillars to be inserted through a stripper and into a female insert assembly. When new products need to be produced, it only needs to replace the female and male insert and the rest parts of the stationary and movable molds don't need to be replaced, thus substantially saving production cost.

2013-02-14

20130040015

TOOLING FOR INJECTION-MOLDING A PART - A tooling for injection-molding a part, the tooling including two cavity blocks each including a cavity formed therein of a shape corresponding to a shape of a part that is to be molded once the cavity blocks have been superposed, at least one of the cavity blocks including an ejection mechanism ejecting the molded part and including at least one ejector movable between a molding position and an ejection position. The ejector is guided to move between its two positions along a curved path, or a circular arc, of shape that corresponds to a shape of a portion of the mold part to be extracted from the cavity.

2013-02-14

20130040016

ALLERGEN-FREE COMPOSITIONS - The present disclosure provides an allergen-free composition (e.g., flours and dough) and baked products made without eggs or any other major food allergen. The disclosed allergen-free flours, dough, and batters overcome the various problems associated with allergen-free baking by appropriate adjustment of the relative amounts of various components that contribute moisture, alkalinity, texture, etc., to the final product. Baked products produced using the allergen-free flours thus have a moistness, springiness, rise, texture, and flavor comparable to products containing major food allergens. Baked products according to the disclosure include, but are not limited to, cookies (e.g., chocolate chunk/chip cookies), cakes (e.g., cupcakes), muffins, pancakes, waffles, pizza crust, pie crust, and bread products.

REDUCED CALORIE AND SUGAR-FREE COATING FOR FOOD PRODUCTS COMPRISING ERYTHRITOL AND A BULKING AGENT - The present invention relates to a coated food composition comprising a food product and a coating, wherein the coating comprises a mixture of erythritol and at least one bulking agent, wherein the erythritol comprises between 20% to 90% by weight of the coating, and wherein the bulking agent comprises between 10% to 80% by weight of the coating, and a method for preparing such a coated food composition.

Methods and Compositions for Preparing Consumables with Optical Shifting Properties - Ingestible compositions comprising a chromic change agent together with methods of making and using them are provided. The chromic change agent alternatively may be associated with the ingestible, such as a packaging material for the ingestible. In response to a triggering event, physical or chemical, the chromic change agent changes color to provide information as to the history of the ingestible, either prior or contemporaneous with use. Depending on the use, the color change agent may be reversible or irreversible. Various solid or liquid ingestible compositions are provided for determining ingestible temperature, storage temperature, user temperature, light exposure, pH change, hydration or solvation change, mechanical stress, and the like, particularly in comestibles. Of particular interest are polydiacetylene polymers that may be formulated to provide compositions having numerous different color transition triggering mechanisms. The invention is also related to other chromic change agents that may be incorporated into ingestibles.

REFRESHED FRUIT AND PRODUCE BARS - The inventions uses preferably dried fruits, makes them ready to use, by chopping, mixing with other fruits and/or produce, fortifying them, forming them into bites and/or bars, wrapping and packing them to make them easy to transport, store, shelf, label, purchase, carry, keep at home, carry in pocket, hold in hand, eat, with little waste or disposal, little or no need for refrigeration, etc. Also a method of moistening dried fruits to make them taste similar to fresh fruit, and fortification to increase nutritional value and other treatments are introduced. A substance laced fruit is introduced to promote fruit and enhance nutrition.

2013-02-14

20130040023

DISTILLER GRAIN PELLET PRODUCTION METHODS - A method for producing a high density compact livestock feed from a loose granular material may include feeding distiller grain into a loading zone and passing the distiller grain into a heating zoned comprising one or more heaters and a rotating screw. The method further includes rotating the screw to transfer the treated material through the heating zone while increasing the compressive force applied to the treated material. The method may further include pressing the treated material through a compression enclosure that simultaneously applies a transverse force and a parallel force onto the treated material to form a high density compact body. The method may then include a cooling process and an extraction process.

2013-02-14

20130040024

Fruit Products, Methods of Producing Fruit Products, Fruit Extraction Systems and Fruit Infusion Systems - A method for producing fruit products. The method includes presenting a fruit comprising at least one water insoluble component and at least one water soluble component. Removing at least a portion of the at least one water soluble component from the fruit, the removing comprising leaving at least a portion of the at least one water insoluble component. Providing at least one polyol in the at least a portion of the at least one water insoluble component.